AUTHOR=Omidi Fatemeh , Hajikhani Bahareh , Kazemi Seyyedeh Neda , Tajbakhsh Ardeshir , Riazi Sajedeh , Mirsaeidi Mehdi , Ansari Ali , Ghanbari Boroujeni Masoud , Khalili Farima , Hadadi Sara , Nasiri Mohammad Javad 

TITLE=COVID-19 and Cardiomyopathy: A Systematic Review

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.695206

DOI=10.3389/fcvm.2021.695206

ISSN=2297-055X

ABSTRACT=<p><bold>Background:</bold> Cardiomyopathies (CMPs) due to myocytes involvement are among the leading causes of sudden adolescent death and heart failure. During the COVID-19 pandemic, there are limited data available on cardiac complications in patients with COVID-19, leading to severe outcomes.</p><p><bold>Methods:</bold> We conducted a systematic search in Pubmed/Medline, Web of Science, and Embase databases up to August 2020, for all relevant studies about COVID-19 and CMPs.</p><p><bold>Results:</bold> A total of 29 articles with a total number of 1460 patients were included. Hypertension, diabetes, obesity, hyperlipidemia, and ischemic heart disease were the most reported comorbidities among patients with COVID-19 and cardiomyopathy. In the laboratory findings, 21.47% of patients had increased levels of troponin. Raised D-dimer levels were also reported in all of the patients. Echocardiographic results revealed mild, moderate, and severe Left Ventricular (LV) dysfunction present in 17.13, 11.87, and 10% of patients, respectively.</p><p><bold>Conclusions:</bold> Cardiac injury and CMPs were common conditions in patients with COVID-19. Therefore, it is suggested that cardiac damage be considered in managing patients with COVID-19.</p>